NASDAQ:CGEM Cullinan Therapeutics (CGEM) Stock Price, News & Analysis → Who are Nvidia’s New Silent Partners? (From Weiss Ratings) (Ad) Free CGEM Stock Alerts $23.50 +0.71 (+3.12%) (As of 05/31/2024 ET) Add Compare Share Share Today's Range$22.58▼$23.7350-Day Range$15.63▼$29.3552-Week Range$7.64▼$30.19Volume948,089 shsAverage Volume631,168 shsMarket Capitalization$1.35 billionP/E RatioN/ADividend YieldN/APrice Target$32.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Get Cullinan Therapeutics alerts: Email Address Cullinan Therapeutics MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside36.2% Upside$32.00 Price TargetShort InterestBearish11.90% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.57Based on 5 Articles This WeekInsider TradingSelling Shares$1.63 M Sold Last QuarterProj. Earnings GrowthDecreasingFrom ($3.02) to ($3.07) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.48 out of 5 starsMedical Sector534th out of 929 stocksBiological Products, Except Diagnostic Industry84th out of 153 stocks 4.5 Analyst's Opinion Consensus RatingCullinan Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 7 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageCullinan Therapeutics has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Cullinan Therapeutics' stock forecast and price target. Previous Next 1.0 Short Interest Percentage of Shares Shorted11.90% of the float of Cullinan Therapeutics has been sold short.Short Interest Ratio / Days to CoverCullinan Therapeutics has a short interest ratio ("days to cover") of 5.Change versus previous monthShort interest in Cullinan Therapeutics has recently increased by 58.47%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldCullinan Therapeutics does not currently pay a dividend.Dividend GrowthCullinan Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for CGEM. Previous Next 2.5 News and Social Media Coverage News SentimentCullinan Therapeutics has a news sentiment score of 0.57. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.80 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 5 news articles for Cullinan Therapeutics this week, compared to 2 articles on an average week.Search Interest9 people have searched for CGEM on MarketBeat in the last 30 days. This is an increase of 125% compared to the previous 30 days.MarketBeat FollowsOnly 2 people have added Cullinan Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Cullinan Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $1,628,060.00 in company stock.Percentage Held by InsidersOnly 6.07% of the stock of Cullinan Therapeutics is held by insiders.Percentage Held by Institutions86.31% of the stock of Cullinan Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Cullinan Therapeutics' insider trading history. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Cullinan Therapeutics are expected to decrease in the coming year, from ($3.02) to ($3.07) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Cullinan Therapeutics is -7.51, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Cullinan Therapeutics is -7.51, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioCullinan Therapeutics has a P/B Ratio of 3.18. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Cullinan Therapeutics' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad The Freeport SocietyBiden Nomination CANCELED?The Hill just published that Joe Biden has received enough delegates to…“clinch the Democratic presidential nomination and all but guaranteeing he will face off against former President Trump again in November.” Why is he all BUT guaranteed the Democratic nomination, in their words?I believe I have the terrifying answer right here. About Cullinan Therapeutics Stock (NASDAQ:CGEM)Cullinan Therapeutics, Inc., a biopharmaceutical company, focuses on developing oncology therapies for cancer patients in the United States. The company's lead program comprises CLN-619, a monoclonal antibody that is in Phase I clinical trial for the treatment of solid tumors. Its development portfolio also includes CLN-049, a humanized bispecific antibody that is in Phase I clinical trial for the treatment of acute myeloid leukemia or myelodysplastic syndrome; CLN-418, a human bispecific immune activator that is in Phase 1 clinical trial for the treatment of multiple solid tumors; and Zipalertinib, a bioavailable small-molecule for treating patients with non-small cell lung cancer. In addition, the company's development products comprise CLN-617, a fusion protein for the treatment of solid tumors; and CLN-978, a T cell engaging antibody for the treatment relapsed/refractory B-cell non-Hodgkin lymphoma. It has license and collaboration agreement with Adimab, LLC to discover and/or optimize antibodies; Harbour BioMed US Inc. for the development, manufacturing, and commercialization of CLN-418; and co-development agreement with Taiho Pharmaceutical Co., Ltd to develop Zipalertinib. Cullinan Therapeutics, Inc. was formerly known as Cullinan Oncology, Inc. and changed its name to Cullinan Therapeutics, Inc. in April 2024. Cullinan Therapeutics, Inc. was incorporated in 2016 and is headquartered in Cambridge, Massachusetts.Read More CGEM Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart CGEM Stock News HeadlinesMay 10, 2024 | insidertrades.comJennifer Michaelson Sells 58,000 Shares of Cullinan Oncology, Inc. (NASDAQ:CGEM) StockMay 26, 2024 | americanbankingnews.comCullinan Therapeutics (NASDAQ:CGEM) Receives "Buy" Rating from HC WainwrightMay 24, 2024 | globenewswire.comCullinan Therapeutics to Participate in Fireside Chat at TD Cowen 5th Annual Oncology Innovation SummitMay 23, 2024 | globenewswire.comCullinan Therapeutics to Present First Data for CLN-619, a Novel Anti-MICA/B Antibody, in Combination with a Checkpoint Inhibitor and Updated Monotherapy Data at ASCO 2024May 19, 2024 | uk.investing.comCullinan Oncology stock target trimmed, maintains Buy ratingMay 16, 2024 | finanznachrichten.deCullinan Therapeutics, Inc.: Cullinan Therapeutics Provides Corporate Update and Reports First Quarter 2024 Financial ResultsMay 16, 2024 | markets.businessinsider.comBuy Rating Affirmed for Cullinan Management Ahead of Key ASCO Presentation and Strong FinancialsMay 16, 2024 | markets.businessinsider.comBuy Rating on Cullinan Management: Promising Pipeline and Strategic Pivot to AutoimmunityMay 16, 2024 | investorplace.comCGEM Stock Earnings: Cullinan Oncology Beats EPS for Q1 2024May 15, 2024 | globenewswire.comCullinan Therapeutics Provides Corporate Update and Reports First Quarter 2024 Financial ResultsMay 9, 2024 | finance.yahoo.comInsider Sale at Cullinan Therapeutics Inc (CGEM): Chief Scientific Officer Jennifer Michaelson ...May 1, 2024 | markets.businessinsider.comBuy Rating Justified: Cullinan Management’s Promising TCE Therapy Paves the Way for Market DominanceMay 1, 2024 | msn.comStifel Initiates Coverage of Cullinan Therapeutics (CGEM) with Buy RecommendationApril 29, 2024 | globenewswire.comCullinan Therapeutics Announces Appointment of Mary Kay Fenton as Chief Financial OfficerApril 24, 2024 | finance.yahoo.comWhy Is Cullinan Therapeutics Stock Trading Higher On Wednesday?April 24, 2024 | globenewswire.comCullinan Therapeutics to Present Clinical Data from Phase 1 Study Evaluating Novel Anti-MICA/B Antibody, CLN-619, as Monotherapy and in Combination with a Checkpoint Inhibitor in Patients with Advanced Solid Tumors at ASCO 2024April 17, 2024 | finanznachrichten.deCullinan Therapeutics, Inc.: Cullinan Therapeutics Announces Strategic Expansion into Autoimmune DiseasesApril 16, 2024 | markets.businessinsider.comBuy Recommendation: Cullinan Management’s Strategic Position in Autoimmune Disease Market with Promising CLN-978 TherapyApril 16, 2024 | bizjournals.comCullinan rebrands with $280M private offering, pivot away from cancerApril 16, 2024 | finance.yahoo.comCullinan changes name, pivots to autoimmune diseaseApril 16, 2024 | markets.businessinsider.comCullinan To Expand Into Autoimmune Diseases, Privately Places $280 Mln; Stock Up In Pre-MarketApril 16, 2024 | markets.businessinsider.comCullinan Shifts Focus From Oncology To Autoimmune Disorders, Raises $280M Via EquityApril 16, 2024 | marketwatch.comCullinan Oncology Shares Jump 21% on Planned Autoimmune Diseases Expansion, Private PlacementApril 16, 2024 | msn.comWilliam Blair Initiates Coverage of Cullinan Oncology (CGEM) with Outperform RecommendationApril 16, 2024 | globenewswire.comCullinan Therapeutics Announces Strategic Expansion into Autoimmune DiseasesSee More Headlines Receive CGEM Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Cullinan Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/14/2024Today5/31/2024Next Earnings (Estimated)8/08/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryN/A Current SymbolNASDAQ:CGEM CUSIPN/A CIK1789972 Webwww.cullinanoncology.com Phone617-410-4650FaxN/AEmployees85Year FoundedN/APrice Target and Rating Average Stock Price Target$32.00 High Stock Price Target$40.00 Low Stock Price Target$26.00 Potential Upside/Downside+36.2%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage7 Analysts Profitability EPS (Most Recent Fiscal Year)($3.13) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-153,160,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-28.65% Return on Assets-27.14% Debt Debt-to-Equity RatioN/A Current Ratio20.33 Quick Ratio20.33 Sales & Book Value Annual Sales$18.94 million Price / Sales71.51 Cash FlowN/A Price / Cash FlowN/A Book Value$7.39 per share Price / Book3.18Miscellaneous Outstanding Shares57,634,000Free Float54,136,000Market Cap$1.35 billion OptionableOptionable Beta-0.01 These 7 Stocks Will Be Magnificent in 2024With average gains of 150% since the start of 2023, now is the time to give these stocks a look and pump up your 2024 portfolio.Get This Free Report Key ExecutivesMr. Nadim Ahmed (Age 56)President, CEO & Director Comp: $1.16MDr. Jeffrey Jones M.B.A. (Age 53)M.D., M.P.H., Chief Medical Officer Comp: $780.32kDr. Patrick A. Baeuerle Ph.D. (Age 66)Co-Founder, Chief Scientific Advisor & Chairman of Scientific Advisory Board Comp: $763.73kMs. Mary Kay Fenton (Age 60)Chief Financial Officer Dr. Jennifer Michaelson Ph.D. (Age 57)Chief Scientific Officer Ms. Jacquelyn L. Sumer J.D. (Age 46)Chief Legal Officer, Chief Compliance Officer & Corporate Secretary Ms. Rose WeldonSenior Vice President of CommunicationsMr. Steve AndreChief Human Resources OfficerDr. Corinne Savill Ph.D. (Age 65)Chief Business Officer Mr. Kevin A. JohnstonChief Technical Operations OfficerMore ExecutivesKey CompetitorsXencorNASDAQ:XNCRMacroGenicsNASDAQ:MGNXBlack Diamond TherapeuticsNASDAQ:BDTXInnate PharmaNASDAQ:IPHASpectrum PharmaceuticalsNASDAQ:SPPIView All CompetitorsInsiders & InstitutionsKennedy Capital Management LLCSold 75,778 shares on 5/16/2024Ownership: 0.196%California State Teachers Retirement SystemSold 1,449 shares on 5/16/2024Ownership: 0.055%Affinity Asset Advisors LLCSold 41,412 shares on 5/15/2024Ownership: 0.600%Price T Rowe Associates Inc. MDBought 820 shares on 5/15/2024Ownership: 0.053%American International Group Inc.Sold 1,223,822 shares on 5/14/2024Ownership: 0.030%View All Insider TransactionsView All Institutional Transactions CGEM Stock Analysis - Frequently Asked Questions Should I buy or sell Cullinan Therapeutics stock right now? 7 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Cullinan Therapeutics in the last year. There are currently 7 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" CGEM shares. View CGEM analyst ratings or view top-rated stocks. What is Cullinan Therapeutics' stock price target for 2024? 7 equities research analysts have issued 1 year target prices for Cullinan Therapeutics' stock. Their CGEM share price targets range from $26.00 to $40.00. On average, they expect the company's share price to reach $32.00 in the next twelve months. This suggests a possible upside of 36.2% from the stock's current price. View analysts price targets for CGEM or view top-rated stocks among Wall Street analysts. How have CGEM shares performed in 2024? Cullinan Therapeutics' stock was trading at $10.19 at the start of the year. Since then, CGEM stock has increased by 130.6% and is now trading at $23.50. View the best growth stocks for 2024 here. Are investors shorting Cullinan Therapeutics? Cullinan Therapeutics saw a increase in short interest in May. As of May 15th, there was short interest totaling 3,740,000 shares, an increase of 58.5% from the April 30th total of 2,360,000 shares. Based on an average daily volume of 753,300 shares, the short-interest ratio is currently 5.0 days. Currently, 11.9% of the company's stock are sold short. View Cullinan Therapeutics' Short Interest. When is Cullinan Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, August 8th 2024. View our CGEM earnings forecast. How were Cullinan Therapeutics' earnings last quarter? Cullinan Therapeutics, Inc. (NASDAQ:CGEM) announced its quarterly earnings data on Thursday, March, 14th. The company reported ($0.54) earnings per share for the quarter, beating the consensus estimate of ($0.96) by $0.42. What ETFs hold Cullinan Therapeutics' stock? ETFs with the largest weight of Cullinan Therapeutics (NASDAQ:CGEM) stock in their portfolio include Virtus LifeSci Biotech Clinical Trials ETF (BBC), Loncar China Biopharma ETF (CHNA), Range Cancer Therapeutics ETF (CNCR) and First Trust Dow Jones Select Microcap Index Fund (FDM).Tema Oncology ETF (CANC). When did Cullinan Therapeutics IPO? Cullinan Therapeutics (CGEM) raised $149 million in an initial public offering (IPO) on Friday, January 8th 2021. The company issued 8,300,000 shares at $17.00-$19.00 per share. Morgan Stanley, SVB Leerink and Evercore ISI served as the underwriters for the IPO and H.C. Wainwright & Co., LLC was co-manager. Who are Cullinan Therapeutics' major shareholders? Cullinan Therapeutics' stock is owned by a number of retail and institutional investors. Top institutional investors include Vanguard Group Inc. (4.12%), Affinity Asset Advisors LLC (0.60%), Kennedy Capital Management LLC (0.20%), California State Teachers Retirement System (0.06%), Price T Rowe Associates Inc. MD (0.05%) and Mirae Asset Global Investments Co. Ltd. (0.04%). Insiders that own company stock include Ansbert Gadicke, Bioscience I 2017 Ltd F2, Bvf Partners L P/Il, Corrine Savill, Jeffrey Alan Jones, Jeffrey Trigilio, Jennifer Michaelson, Leigh Zawel, Nadim Ahmed, Oncology Impact Fund LP Ubs and Vision Scs F2. View institutional ownership trends. How do I buy shares of Cullinan Therapeutics? Shares of CGEM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:CGEM) was last updated on 6/1/2024 by MarketBeat.com Staff From Our PartnersThe ONE AI Stock to own now. (It’s not Nvidia.)Weiss RatingsThe #1 Crypto That You Don’t Own… YetCrypto 101 MediaBiden Nomination CANCELED?The Freeport SocietyMAJOR BUY SIGNAL: Move Fast, Washington/Pelosi/Mill…AltimetryUnlock Explosive Gains with This Defense StockBehind the MarketsMust-See: Elon’s New Invention is Absolutely InsaneInvestorPlaceClaim Your Complimentary Bitcoin RewardCrypto Swap ProfitsTrump’s Gift Could Unleash $51 Billion in New WealthWealthpin Pro Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cullinan Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
